The Company's management and scientific advisory teams have a unique and extensive expertise in complex carbohydrate chemistry, regulatory and clinical development, with multiple submissions and approvals to U.S. Food and Drug Administration. The executive management team and officials have more than 100 years of combined experience.
Carl W. Rausch
Chief Executive Officer
August 2016 to 2017, Mr. Rausch is the CEO of Boston Therapeutics, overseeing operations in the US and in Asia. Deeply involved in the restructuring of Boston Therapeutics with an overhaul of operations for manufacture, clinical and regulatory as well as exploratory marketing. In 2014 to present, Mr. Rausch served as Managing Principal Partner of World Technology East II Ltd (WTE II), a Hong Kong based consulting firm involved with all aspects of biopharmaceutical product development, registration and licensing in various territories in Asia including Korea, Taiwan, Singapore, Myanmar, Brunei, Malaysia, Japan, China and Australia. In 2014, Mr Rausch also served as the Principal of Medical Technology Associates II (MTA II), a Delaware corporation involved in the licensing, research development as well as manufacturing and marketing of innovative technology driven high technology processes in biologics and diagnostics.
Mr Rausch has founded two biotechnology companies focused in the implementation and execution of new business opportunities related to biologic therapeutics, diagnostics and clinical research in areas of unmet medical needs. For the past decade, Mr. Rausch has served as an independent consultant for biopharmaceutical industrial clients, university based development facilities and contract research organizations for preclinical and clinical strategic management of investigative biological materials for registration with the European Medicines Agency and the US Food and Drug Administration. From 2008-2014, Mr Rausch served as Chief Scientific and Business (Consultancy) Advisor of New-a-Innovation (“NewAi”), a Hong Kong based biotechnology company involved in the drug and diagnostic development in the veterinary and human healthcare field. His main role at NewAi involved coordinating and executing preclinical and clinical trials as well as manufacturing related to global regulatory registration. Mr Rausch has been both a coach and a player coach scientifically, financially and organizationally and has been able to work as independent advisor to many biotechnology clients.
Mr. Rausch Co-founded of Biopure Corporation (“Biopure”) in 1984 and served as the Chairman, President, Vice Chairman and Chief Technical Officer of Biopure from 1984 to 2002 to 2005. Biopure grew to a market capitalization of over $1.2 billion USD in 2000 and left the leadership role in 2002. Prior years Mr. Rausch was Vice President, Preparative and Process Chromatography Division, at Millipore Corporation, and held senior positions at the chromatographic instrument supply company, Water Associates (Waters Corporation 2017), where he contributed to patented and process technology. He holds advanced degrees, M.S. degree in chemical engineering from the Massachusetts Institute of Technology and holds an M.S. degree in medical engineering and a B.S. degree in chemical engineering from Tufts University.
Loraine V. Upham
As the founding CEO of CureDM, now a wholly owned subsidiary of Boston Therapeutics, Ms. Upham successfully raised funding and engineered partnerships to conduct basic research and establish the proof of concept for BTI-410 (HIP2B), which allowed for progression of the compound from preclinical development to a Phase 2 ready clinical candidate. She successfully managed and executed all preclinical activities required for IND. She was a key and integral part in every facet of CureDM’s business, science and technology.
Her 30-year career in the Pharmaceutical and Biotechnology Industry includes Molecular Genetics Research at Eli Lilly and Company, Marketing and Sales at Merck and Co. and then ventured into the realm of smaller companies both in the device and biotechnology areas, including a decade of product management in nuclear and fluorescence detection instrumentation and assay development at Packard BioScience (now Perkin Elmer), and two years in process and business development at Prolexys Pharmaceuticals, developing a human protein interaction database. Ms. Upham is a co-inventor on the CureDM intellectual property portfolio with a BA in Biology from University of Pennsylvania and an MBA from Arizona State University.
Acting Chief Financial Officer
Former CFO for Orion Seafood International.
High level Finance Positions for several small to midsize companies both public and private BSBA and MBA from Boston University